

sTable 1. Baseline Characteristics of Patients grouped by onset to treatment times and treatments.

	Onset to Treatment Times			Onset to Treatment Times			Onset to Treatment Times		
	0-90 min			91-180 min			181-270 min		
	Tenecteplase (N=43)	Alteplase (N=41)	P value	Tenecteplase (N=310)	Alteplase (N=312)	P value	Tenecteplase (N=354)	Alteplase (N=352)	P value
Mean Age -yr	61.6±11.3	63.2±9.3	0.39	66.0±11.7	64.3±11.3	0.03	65.5±11.2	65.6±11.3	0.88
Age group -yr			0.16			0.13			0.65
18-59	19 (44.2)	15 (36.6)		88 (28.4)	108 (34.6)		104 (29.4)	93 (26.4)	
60-79	21 (48.8)	26 (63.4)		184 (59.4)	177 (56.7)		215 (60.7)	225 (63.9)	
≥80	3 (7.0)	0 (0.0)		38 (12.3)	27 (8.7)		35 (9.9)	34 (9.7)	
Male Sex - no. (%)	31 (72.1)	28 (68.3)	0.70	208 (67.1)	212 (67.9)	0.82	251 (70.9)	237 (67.3)	0.30
Weight (IQR) - kg	62(54-68)	68.3(60-76)	0.72	66(57.5-75)	68.0(60-75)	0.04	65(58.7-75)	65.0(58-75.5)	0.61
Medical history- no. (%)									
Hypertension	32 (74.4)	31 (75.6)	0.90	213 (68.7)	225 (72.1)	0.25	262 (74.0)	255 (72.4)	0.64
Diabetes mellitus	11 (25.6)	12 (29.3)	0.70	74 (23.9)	92 (29.5)	0.11	85 (24.0)	103 (29.3)	0.11
Hyperlipidemia	8 (18.6)	9 (22.0)	0.70	59 (19.0)	79 (25.3)	0.06	61 (17.2)	71 (20.2)	0.32
Coronary heart disease	7 (16.3)	10 (24.4)	0.36	84 (27.1)	72 (23.1)	0.25	74 (20.9)	84 (23.9)	0.35
Arrhythmia	4 (9.3)	6 (14.6)	0.52	68 (21.9)	71 (22.8)	0.81	63 (17.8)	69 (19.6)	0.54
Current smoking - no. (%)	17 (39.5)	18 (43.9)	0.90	111 (35.9)	117 (37.5)	0.89	137 (38.7)	139 (39.6)	0.97
History of medication use - no. (%)									
Antiplatelet agents	6 (14.0)	4 (9.8)	0.74	40 (12.9)	42 (13.5)	0.84	44 (12.4)	46 (13.1)	0.80
Anticoagulant agents	1 (2.3)	0 (0.0)	>0.99	0 (0.0)	2 (0.6)	0.50	4 (1.1)	5 (1.4)	0.75

Antihypertensive drugs	21 (48.8)	20 (48.8)	>0.99	118 (38.1)	138 (44.2)	0.12	157 (44.4)	160 (45.5)	0.77
Hypoglycemic drugs	6 (14.0)	5 (12.2)	0.81	53 (17.1)	56 (17.9)	0.78	47 (13.3)	57 (16.2)	0.27
Lipid-lowering drugs	6 (14.0)	4 (9.8)	0.74	27 (8.7)	26 (8.3)	0.87	34 (9.6)	30 (8.5)	0.62
Pre-stroke mRS - no. (%)			0.48			0.25			0.54
0	40 (93.0)	36 (87.8)		278 (89.7)	288 (92.3)		314 (88.7)	307 (87.2)	
1	3 (7.0)	5 (12.2)		32 (10.3)	24 (7.7)		40 (11.3)	45 (12.8)	
NIHSS score*									
Median (IQR)	7(6-10)	9(6-11)	0.14	7(5-10)	7(6-10)	0.47	7(5-10)	7(6-10)	0.23
Mild (≤7)	23 (53.5)	14 (34.1)	0.21	171 (55.2)	169 (54.2)	0.67	224 (63.3)	203 (57.7)	0.28
Moderate (8-14)	18 (41.9)	25 (61.0)		108 (34.8)	117 (37.5)		100 (28.2)	118 (33.5)	
Severe (≥15)	2 (4.7)	2 (4.9)		31 (10.0)	26 (8.3)		30 (8.5)	31 (8.8)	
Onset-to-needle time (IQR) - min	75(60-85)	75(66-82)	0.73	140(118-161)	140(116.5-161)	0.79	221.5(200-245)	230(209-250)	0.005
Door-to-needle time -min	45(39-55)	48(40-57)	0.44	55(45-71)	60(48-78)	0.02	63.5(45-88)	65(49-91)	0.19
Bridging thrombectomy	2 (4.7)	5 (12.2)	0.26	13 (4.2)	11 (3.5)	0.67	12 (3.4)	7 (2.0)	0.25

IQR denotes interquartile range.

\* National Institutes of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating more severe stroke.

**sFigure 1. Enrollment and Randomization**